Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.